Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case

Cristina Santoro; Paola Volpicelli; Erminia Baldacci; Grazia Ferrara; Alice Di Rocco; Antonietta Ferretti; Marika Porrazzo; Maria Gabriella Mazzucconi

doi:10.1002/ccr3.920

Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case

Clin Case Rep. 2017 Jul 13;5(8):1385-1388. doi: 10.1002/ccr3.920. eCollection 2017 Aug.

Authors

Cristina Santoro¹, Paola Volpicelli¹, Erminia Baldacci¹, Grazia Ferrara¹, Alice Di Rocco¹, Antonietta Ferretti¹, Marika Porrazzo¹, Maria Gabriella Mazzucconi¹

Affiliation

¹ Hematology Department of Cellular Biotechnology and Hematology "Sapienza" University of Rome Italy.

Abstract

Thrombopoietin receptor agonists (TPO-RAs) are used as effective alternative treatments in ITP patients unresponsive to first-/second-line therapies. TPO-RAs can also be used to normalize platelet count to safely perform invasive procedures and chemotherapy, in case of malignancies. In few responsive patients, TPO-RAs can be suspended maintaining a sustained response.

Keywords: Eltrombopag; ITP; TPO‐RA; therapy.

Publication types

Case Reports